Percutaneous argon-helium cryoablation combined with systemic chemotherapy in the treatment of stage III B/IV lung squamous cell carcinoma: Analysis of curative effect

Fei Cao, Yan Wang, Changfu Liu, Haipeng Yu, Xueling Yang, Tongguo Si, Zhi Guo

    Research output: Contribution to journalArticle

    Abstract

    Objective To discuss the efficacy and safety of CT-guided percutaneous argon-helium cryoablation combined with systemic intravenous chemotherapy in the treatment of advanced lung squamous cell carcinoma (LSCC). Methods The clinical date of 77 patients with stage IIlB/IV LSCC, who were admitted to authors' hospital during the period from January 2014 to January 2017 to receive treatment, were enrolled in this study. According to treatment regimens, the patients were divided into the control group (n- 43) and the combination group (n=34). For patients of the control group simple systemic intravenous chemotherapy was adopted, and for patients of the combination group argon - helium cryoablation combined with systemic intravenous chemotherapy was carried out. The objective remission rate (ORR), the disease control rate (DCR), progression-free survival (PFS), overall survival (OS), the incidence of adverse reactions and the changes in quality of life were compared between the two groups. Results The ORR and DCR of the combination group were 64.7% and 85.3% respectively, which of the control group were 41.9% and 67.4% respectively, the differences in ORR and DCR between the two groups were statistically significant (/J<0.05). The median PFS and OS in the combination group were 10 months (95%CI: 8.69-11.3! months) and 20 months (95%CI: 17.79-22.20 months) respectively, which in the control group were 7 months (95%CI:6.07- 7.92 months) and 15 months (95% CI: 13.62-16.38 months) respectively, and statistically significant differences in PFS and OS existed between the two groups (P<0.05). No statistically significant difference in the incidence of adverse reactions to chemotherapy existed between the two groups (P<0.05), indicating that cryoablation did not increase the incidence of adverse reactions to chemotherapy, but cryoablation could remarkably improve the quality of life of patients. Conclusion Compared with pure systemic intravenous chemotherapy, percutaneous argon-helium cryoablation combined with systemic intravenous chemotherapy is strikingly effective for advanced LSCC, moreover, on the basis of not increasing the incidence of adverse reactions to chemotherapy, the quality of life of patients can be significantly improved and the PFS and OS can be remarkably prolonged.(J Intervent Radiol, 2018, 27: 1045-1050).

    Original languageEnglish (US)
    Pages (from-to)1045-1050
    Number of pages6
    JournalJournal of Interventional Radiology (China)
    Volume27
    Issue number11
    DOIs
    StatePublished - Nov 2018

      Fingerprint

    Keywords

    • Cryoablation
    • Intravenous chemotherapy
    • Lung squamous cell carcinoma
    • Stage iiib/IV

    ASJC Scopus subject areas

    • Radiology Nuclear Medicine and imaging

    Cite this